Key result
Hepatectomy for primary hepatic angiosarcoma resulted in postoperative survival times of 8 and 16 months in two patients, supporting complete surgical resection as the mainstay treatment.
Case Report (n=2)
No
Complete surgical resection is endorsed as the mainstay definitive treatment for primary hepatic angiosarcoma, with adjuvant chemotherapy potentially improving survival.
May inform rare-case management; leaves open need for prospective validation of resection benefit.
Primary hepatic angiosarcoma (PHA) is a rare malignancy that carries a poor prognosis. Of 1500 patients who underwent hepatectomy for primary hepatic tumors between 1994 and 2013 at our center, two patients were pathologically diagnosed with PHA. Clinical characteristics, treatment modalities, and outcomes of the two patients were collected and analyzed. Both patients underwent hepatectomy and had a postoperative survival time of 8 and 16 mo, respectively. A search of PubMed yielded eight references reporting 35 cases of PHA published between 2004 and 2013. On the basis of the presented cases and review of the literature, we endorse complete surgical resection as the mainstay definitive treatment of PHA, with adjuvant postoperative chemotherapy potentially improving survival. Palliative chemotherapy is an option in advanced hepatic angiosarcoma.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2015) conducted a case report in Primary hepatic angiosarcoma (n=2). Hepatectomy was evaluated on Postoperative survival time. Hepatectomy for primary hepatic angiosarcoma resulted in postoperative survival times of 8 and 16 months in two patients, supporting complete surgical resection as the mainstay treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: